- Home
- LNT vs BMRN Comparison
LNT vs BMRN Comparison
Compare LNT & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNT
- BMRN
- Stock Information
- Founded
- LNT 1917
- BMRN 1996
- Country
- LNT United States
- BMRN United States
- Employees
- LNT N/A
- BMRN N/A
- Industry
- LNT Power Generation
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- LNT Utilities
- BMRN Health Care
- Exchange
- LNT Nasdaq
- BMRN Nasdaq
- Market Cap
- LNT 14.9B
- BMRN 13.7B
- IPO Year
- LNT N/A
- BMRN 1999
- Fundamental
- Price
- LNT $60.80
- BMRN $59.17
- Analyst Decision
- LNT Hold
- BMRN Buy
- Analyst Count
- LNT 8
- BMRN 22
- Target Price
- LNT $63.19
- BMRN $94.00
- AVG Volume (30 Days)
- LNT 2.2M
- BMRN 2.0M
- Earning Date
- LNT 05-08-2025
- BMRN 05-01-2025
- Dividend Yield
- LNT 3.34%
- BMRN N/A
- EPS Growth
- LNT N/A
- BMRN 153.71
- EPS
- LNT 2.69
- BMRN 2.21
- Revenue
- LNT $3,981,000,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- LNT $7.84
- BMRN $12.23
- Revenue Next Year
- LNT $3.84
- BMRN $9.93
- P/E Ratio
- LNT $22.60
- BMRN $26.81
- Revenue Growth
- LNT N/A
- BMRN 17.97
- 52 Week Low
- LNT $47.23
- BMRN $52.93
- 52 Week High
- LNT $66.54
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- LNT 44.51
- BMRN 37.64
- Support Level
- LNT $60.28
- BMRN $52.93
- Resistance Level
- LNT $62.38
- BMRN $60.93
- Average True Range (ATR)
- LNT 1.91
- BMRN 3.18
- MACD
- LNT -0.17
- BMRN -0.53
- Stochastic Oscillator
- LNT 42.99
- BMRN 34.01
About LNT Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electric customers and 425,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.